Head-to-head: Dynatronics (NASDAQ:DYNT) versus Antares Pharma (NASDAQ:ATRS)


Dynatronic (NASDAQ:DYNTreceived rating) and Antares Pharma (NASDAQ: ATRSreceived rating) are both small medical companies, but which one is the better investment? We’ll compare the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability, and analyst ratings.


This table compares the net margins, return on equity and return on assets of Dynatronics and Antares Pharma.

net margins return on equity return on investment
Dynatronic 4.50% 12.52% 5.37%
Antares Pharma 25.16% 12.33% 7.83%

Score & Rating

This table compares the revenue, earnings per share, and valuation of Dynatronics and Antares Pharma.

gross receipts price/sales ratio net income earnings per share price-earnings ratio
Dynatronic $47.80 million 0.27 $2.00 million $0.09 8.00
Antares Pharma $183.98 million 5.14 $46.29 million $0.27 20.59

Antares Pharma has higher sales and profits than Dynatronics. Dynatronics is trading at a lower price-to-earnings multiple than Antares Pharma, suggesting it’s the cheaper of the two stocks at the moment.

Analyst Recommendations

This is a breakdown of the current recommendations for Dynatronics and Antares Pharma as provided by MarketBeat.

sell reviews keep ratings Buy reviews Strong buy recommendations rating score
Dynatronic 0 0 2 0 3.00
Antares Pharma 0 5 0 0 2.00

Dynatronics currently has a consensus price target of $3.00, which suggests a potential upside of 316.67%. Antares Pharma has a consensus price target of $5.60, which suggests a potential upside of 0.72%. Given Dynatronics’ stronger consensus rating and more likely upside potential, analysts clearly believe Dynatronics is cheaper than Antares Pharma.

Institutional and Insider Ownership

10.0% of Dynatronics shares are owned by institutional investors. In comparison, 48.6% of Antares Pharma’s shares are owned by institutional investors. Insiders own 11.2% of Dynatronics shares. In comparison, 5.9% of Antares Pharma’s stock is owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers, and endowments believe a stock is poised for long-term growth.

volatility and risk

Dynatronics has a beta of -0.06, meaning its stock price is 106% less volatile than the S&P 500. In comparison, Antares Pharma has a beta of 1.52, meaning its stock price is 52% more volatile than the S&P 500.


Antares Pharma beats Dynatronics on 9 of the 14 factors compared between the two stocks.

About Dynatronics (received rating)

Dynatronics Corporation, a medical device company, designs, manufactures, and markets physical therapy, rehabilitation, orthopedic, pain management, and athletic training products in the United States. Orthopedic soft bracing products include neck braces, shoulder immobilizers, arm slings, wrist and elbow braces, abdominal and lumbosacral braces, maternity braces, knee immobilizers and braces, ankle walkers and braces, plantar fasciitis splints and cold therapy products. The Company offers therapeutic modality devices that include electrotherapy, ultrasound, phototherapy, therapeutic lasers, shortwave diathermy, radial pulse therapy, heat and cold therapy, compression therapy and electrodes. It also offers electric and manual treatment tables, mat platforms, work tables, parallel bars, exercise stairs, dumbbell racks, treadmills and other related equipment. In addition, the Company provides clinical consumables including exercise tapes and tubes, lotions and gels, orthopedic supports, paper products and other related consumables. It markets its products under the Bird & Cronin, Solaris, Hausmann, Physician’s Choice and PROTEAM brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine specialists, clinics and hospitals, and online. It also exports its products to about 30 countries. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

About Antares Pharma (received rating)

Antares Pharma logoAntares Pharma, Inc., a specialty pharmaceutical company, is primarily focused on the development and commercialization of pharmaceutical products and technologies that address the needs of patients in specific therapeutic areas. It develops, manufactures and markets novel therapeutic products using its drug delivery systems. The Company’s injectable products include XYOSTED, for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP, a methotrexate subcutaneous injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe refractory psoriasis; and NOCDURNA sublingual tablets, for the treatment of nocturia due to nocturnal polyuria in adults who wake up to urinate at least twice a night. Its injection products also include generic Epinephrine Injection USP products, indicated for the emergency treatment of severe allergic reactions, including anaphylaxis, in adults and certain pediatric patients; Sumatriptan Injection USP Indicated for the Acute Treatment of Migraine and Cluster Headaches in Adults; and Makena subcutaneous auto-injector drug combination product indicated to reduce the risk of preterm birth in women and teriparatide injection for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures and glucocorticoid-induced osteoporosis in men and women. In addition, the company is developing disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO for the treatment of deficiency or lack of endogenous testosterone in adult men; and drug/device products for urological oncology, immunology and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd and AMAG. Antares Pharma, Inc. was founded in 1979 and is headquartered in Ewing, New Jersey.

Receive News & Reviews for Dynatronics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dynatronics and related companies with MarketBeat.com’s FREE daily email newsletter.


Comments are closed.